Commercial opportunities with the EpimiRNA consortium
MicroRNAs in the pathogenesis, treatment and prevention of epilepsy under an epileptogenic insult
As a leading research initiative in epilepsy (16 million €; US$ 20 million), the EpimiRNA consortium supported by European Commission offers you an outstanding opportunity to be a part of it and be first to share its results. Therefore, the consortium is now open for future commercial partners such as multinational Health Care companies, specialized small and mid size enterprises, patient organizations and foundations to maximize the impact of the program and gain value for all stakeholders.
You or your organization as an Associated Partner create the following advantages:
· Commercialize and make the consortium’s results rapidly available to patients;
· Augment and accelerate the scientific and clinical research of the individual work packages in the consortium;
· Leverage consortium members’ expertise, capabilities and work package results in adjacent areas to benefit patients, their families and the scientific and clinical communities.
A partnership could encompass the entire array of the consortium’s activities (ranging from drug discovery component, a translation phase to clinical trials/applications) or be focused on one or several of its nine work packages. The consortium aims for a collaborative and tailored partnership structure as Associated Partner.
Picture: Model as offering to third parties utilization of consortia's intellectual property right (IP) for commercialization towards beneficial treatment of epilepsy patient.
In case you are interested in partnering opportunities to boost epilepsy treatment please contact to:
David Henshall, Ph.D.
Professor of Molecular Physiology and Neuroscience
RCSI Physiology & Medical Physics Dept
Royal College of Surgeons in Ireland
123 St. Stephen's Green,
Phone: +353 1 4028629
For US and America:
Michael Bogenstaetter, Ph.D. (Scientific Advisory Member of the EpimiRNA consortium)